Drugs / MG1-MAGEA3
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03773744 | Feb → Oct 2020 | metastatic melanoma, skin squamous cell carcinoma | Turnstone Biologics, Corp. | Withdrawn | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02879760 | Mar 2017 → Feb 2020 | non-small cell lung carcinoma | Turnstone Biologics, Corp. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MG1-MAGEA3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02879760 ↗ |
| Route | Intravenous | “MG1/MAGEA3 boost will be administered IV on Day 15 and Day 18 by 5 cohorts” NCT02879760 ↗ |